The Gray Market: Sourcing, Purity, and Contamination

Most “research peptides” sold online travel through a supply chain that’s set up to look like it’s selling lab chemicals, while really selling to regular people. Folks turn to it for reasons that make sense. Maybe a compound looks promising in early research but has no approved product yet, no doctor willing to prescribe it, or a brand-name price that’s just too high. This page isn’t trying to talk you out of anything or judge your choices. It’s here to explain how the market actually works so you can size up what you’re holding. This is reference and harm-reduction information, not medical advice, and nothing here is a how-to or a protocol.

How the supply actually works

A big share of research peptides are made in bulk at large facilities (many of them overseas), sold to middlemen, and then divided into small vials under different brand names. By the time they reach you, they’re labeled “Research Use Only” (RUO) or “not for human consumption.” That phrase is a legal cover, not a measure of quality. It lets a seller skip the testing, sterility, and labeling rules that apply to real drugs, while quietly leaving it up to you to decide what to do with it. The FDA doesn’t take that disclaimer at face value. In September 2025 it sent out more than 50 warning letters to companies selling compounded GLP-1 drugs and other peptides, with most going out on September 9, 2025. Another part of that crackdown went after RUO-labeled products whose own ads made it obvious the items were meant for people — for example, promising weight-loss benefits or otherwise pointing to human use. In its December 2024 letter to Summit Research Peptides, the FDA decided that the company’s website and social-media claims showed the products were “intended to be drugs for human use,” despite the research-use disclaimer.

RUO labeling means no one has to confirm what’s actually in the vial, that it’s the right molecule, that it’s sterile (free of living germs), or that one batch matches the next.

Why purity and even identity vary

Making peptides is error-prone. They’re built one piece at a time in a process called solid-phase synthesis, and each step can fail. That leaves behind shortened chains, chains missing a piece, leftover protective bits, and other junk that ends up in the final product. Purity is usually measured by HPLC, a lab method that shows how much of the sample is the main ingredient (the “main peak”). Identity is checked by mass spectrometry, a method that confirms whether that main ingredient is actually the molecule it’s supposed to be. A certificate of analysis (a lab report a seller provides) that shows only HPLC tells you something is present at a certain level — not that it’s the compound you ordered.

This isn’t just a worry on paper. The testing firm Finnrick looked at more than 5,000 peptide samples, in work reported by MIT Technology Review in February 2026. It found that some vials sold as BPC-157 contained none of the compound at all. Among the ones that did contain it, measured purity ranged from about 82% to 100%. Quality varied not only from one seller to another, but between batches from the same seller.

Contamination is a separate problem

Purity and sterility are two different things, and both matter for anything you inject. The same Finnrick analysis found that 8% of the peptide samples it tested carried measurable endotoxins. Endotoxins are pieces of dead bacteria cell walls. They hold up to heat and are small enough to slip through a sterilizing (0.22-micron) filter, so they can survive steps that kill living bacteria, including autoclaving (high-heat sterilizing). Endotoxins can cause fever and chills, and in larger amounts they can cause dangerous drops in blood pressure. A vial can be free of living bacteria and still cause a fever reaction, because killing germs and removing endotoxins are not the same job. Beyond endotoxins, the FDA has warned that compounded “semaglutide” can contain unknown impurities (one manufacturer’s analysis cited by Pharmacy Times found levels reaching 33%) and unapproved salt forms such as semaglutide sodium and semaglutide acetate. The FDA calls these different active ingredients from the approved drug, and they haven’t been shown to be safe or effective.

Mislabeling and the limits of “technique”

Because even the identity is unreliable, a vial might hold the wrong peptide, a mix of things, a different salt form, or filler. No amount of careful mixing math, clean handling, or proper storage can fix bad starting material. Reconstitution — mixing the powder with liquid — really is just arithmetic: concentration equals the amount of peptide divided by the amount of liquid you add. But that math only means something if the labeled amount and identity are actually true. Good technique on top of an unknown input just gives you a precisely measured unknown.

Legal and sport status

These products are not approved for human use. BPC-157 was added to the WADA Prohibited List in 2022 under category S0 (Non-Approved Substances) — in fact it was the first substance named as an example in that section — and is banned at all times in WADA-governed sport. USADA points out there’s no way to get a therapeutic use exemption for it, because it isn’t an approved treatment in any country, and it warns athletes never to use a product sold for “research only.” Many growth-hormone secretagogues and releasing peptides — for example ipamorelin, the GHRPs, CJC-1295, and ibutamoren (MK-677) — fall under a separate category, S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).

Bottom line

None of this is a judgment on the compounds themselves. “Unapproved” usually just means a molecule hasn’t gone through the trials that approval requires — often because no company has a business reason to pay for them — not that it’s been shown to be dangerous. The simpler, practical point is this: in the gray market, the label tells you what a seller is allowed to claim, not what’s in the vial. Purity, identity, and sterility all vary, sometimes a lot, and no amount of skill makes up for a contaminated or mislabeled input. Sending a sample to an independent lab is the one move that swaps a seller’s claim for an actual measurement.

Sources

• FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• Health Law Alliance — FDA Targets GLP-1 and Peptide Compounding, Advertising and “Research Use Only” Labeling
• FDA — Warning Letter, Summit Research Peptides (695607), 12/10/2024
• MIT Technology Review — Peptides are everywhere. Here’s what you need to know. (Feb 2026)
• USADA — BPC-157: Experimental Peptide Creates Risk for Athletes
• WADA — The Prohibited List
• Pharmacy Times — Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients
• Peptide purity testing: HPLC quantifies the main peak; mass spectrometry confirms identity; common synthesis byproducts include truncated and deletion sequences (general analytical-chemistry reference; no single canonical URL)